Scienion and Genomica Expand Collaboration
News Nov 07, 2012
This new platform combines Scienion's non-contact arraying and surface technologies with Genomica's multiplex PCR technology and microarrays detection. Both enterprises will advance in the development of new molecular applications, among which, in vitro diagnostics and personalized medicine will lead the way.
Berlin, Germany, and Madrid, Spain, November 5, 2012: Dr. Holger Eickhoff, CEO of Scienion AG, stated: “The technologies of our companies optimally complement one another. Genomica has an excellent track record of successfully marketed DNA-based IVD tests and with its CLART® technology products the company is considered a benchmark in molecular diagnostics. Combining this expertise with Scienion’s state of the art non-contact dispensing technology, our consumables such as high quality microtiter plates and our production capabilities adds up to a perfect match. We are aiming to speed up the development of better and safer in vitro diagnostics and will offer joint technology solutions for the benefit of users and last but not least also for patients.”
Dr. Rosario Cospedal, CEO of Genomica S.A.Unipersonal, added: “Both companies meet the highest quality standards in the development, manufacturing and commercialization of their products. Genomica has a highly competitive technology based on multiplex PCR and microarrays detection. The ability of this technology to detect specific targets with high sensitivity and specificity has allowed our company to expand its market and be competitive in the molecular diagnostics field. Our existing collaboration with Scienion, a trustable and expert company in non-contact printing technology, has already proved to be a good partnership. The close and constructive cooperation between both companies is making possible to identify more subareas for joint activities and we move forward to tap the full potential”.
Based on this new printing plate technology, Scienion and Genomica will jointly offer new services for customers in the microarrays life science industry. These services range from assay development to manufacturing of microarrays individually tailored to the needs and specifications of customers.
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE